- The Dispatch @ DiscussPharma
- Posts
- The Pharma Dispatch 💊 - Issue #86
The Pharma Dispatch 💊 - Issue #86
The FDA continued its potentially record-breaking, magic mushrooms as a cure for depression, a $25,000 life-extension test and other interesting reads from this week.
General
Be very, very concerned about what Allergan just did. Link
The FDA continued its record-breaking pace of new drug approvals by green-lighting the first-ever biosimilar. Link
Most experimental drugs approved in the U.S and Canada are tested offshore. Link
Astra's Farxiga results may open up type 1 diabetes opportunity. Link
The FDA is changing the way it approves medicines for rare diseases. Link
Pfizer, Astellas prostate cancer drug promising in late-stage trial. Link
A new type of heart drug from Moderna and AstraZeneca makes a promising first step. Link
The battle against Cancer: the science is advancing but the economics are holding us back. Link
Digital Health
This startup is trying to 3D print human organs. Link
The first mobile addiction treatment app is about to hit the market. Link
New Amazon patent points to wireless heart rate detection. Link
Research
Magic mushrooms as a cure for depression. Link
How bacteria could protect tumors from anticancer drugs. Link
Perspective and Opinions
Could a new field of ‘immuno-neurology’ be on the horizon? Link
The new clinical trials site: Doctor's offices? Link
Medicine and the need for Artificial Intelligence. Link
Interesting
Male infertility crisis in the U.S. has experts baffled. Link
A $25,000 life-extension test. Link
What would it cost to transplant each organ in the body? Link
Startups of the Week
The company aims to introduce a novel biochemical process for DNA and RNA synthesis based on the use of efficient enzymes. This technology mimics the way nature produces genetic code and enables enhanced performance while minimizing the use of harsh chemicals.
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs.
Grid is developing a human-derived targeted immunotherapy which leverages a novel approach of identifying specific tumor immunoglobulin G (IgG) antibodies from patients with early-stage cancer.
SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with CAR-T therapies.
Our digital times :)
